Acorda inks Ampyra generic pacts as Ampyra appeal pends by Carly Helfand Monday, August 6, 2018 Late last month, a court refused to block copies of Acorda’s Ampyra. So the New York drugmaker took matters into its own hands.
CEO: Win or lose on Ampyra, Acorda's reps are safe with Inbrija by Carly Helfand Wednesday, June 6, 2018 Even if Acorda loses its upcoming appeal on Ampyra's patents, its sales force won’t have to worry, CEO Ron Cohen says.
Activist presses Ampyra maker Acorda to put itself on the block by Tracy Staton Monday, August 7, 2017 After Acorda lost a key patent fight, putting its $493 million drug Ampyra in danger, a hedge fund is pushing the biotech to sell out.
Novartis' MS med Gilenya falls in patent appeal by Eric Sagonowsky Thursday, April 13, 2017 Novartis loses Gilenya patent appeal, clearing way for early copies of the $3 billion multiple sclerosis med.
With key drug Ampyra under threat, Acorda plots 100 job cuts by Carly Helfand Wednesday, April 5, 2017 Acorda Therapeutics plans to appeal a court’s recent decision to nix four of its five Ampyra patents. In the meantime, it’s preparing for the worst.
Court nixes Ampyra patents, teeing up 2018 generics by Carly Helfand Monday, April 3, 2017 Acorda Therapeutics’ IP protection on Ampyra may have held up against an administrative patent challenge, but it didn't do the same in court.
Acorda wins big over thwarted patent challenger Bass by Carly Helfand Friday, March 10, 2017 Acorda Therapeutics can chalk up another win over patent challenger Kyle Bass and his Coalition for Affordable Drugs.
